Cytokines, interleukin-18, and the genetic determinants of vascular inflammation

Circulation

Volumn 112, Issue 5, 2005, Pages 620-623

  Anderson, Jeffrey L ^a   Carlquist, John F ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Editorials; Genetics; Inflammation; Interleukins

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; PHOSPHOLIPASE A2; SERUM AMYLOID A;

ACUTE PHASE RESPONSE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EDITORIAL; HAPLOTYPE; HEREDITY; HUMAN; INFLAMMATION; MACROPHAGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THROMBOSIS;

ATHEROSCLEROSIS; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-18; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR DISEASES;

EID: 23244460914     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.554733     Document Type: Editorial

References (20)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1628-1643.
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY. Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Tauben K, Tracy RP, Vinicor F: Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
4. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
5. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41:1475-1479.
6. Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol. 2001;87:129-135.
7. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003;33:177-182.
8. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001;29:306-309.
9. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet. 2001;29:229-232.
10. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA. Haplotype tagging for the identification of common disease genes. Nat Genet. 2001;29:233-237.
11. Tiret T, Godefroy T, Lubos E, Nicaud V, Tregouet D-A, Barbaux S, Schnabel R, Bickel S, Espinola-Klein C, Poirier O, Perret C, Münzel T, Rupprecht H-J, Lackner K, Cambien F, Blankenberg S, for the AtheroGene Investigators. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005;112:643-650.
12. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine tha stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12:53-72.
13. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol. 2005;25:791-796.
14. Whitman SC, Ravisankar P, Daugherty A. InterIeukin-18 enhances atherosclerosis in apolipoprotein E (-/-) mice through release of interferon-gamma. Circ Res. 2002;90:e34-e38.
15. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001;89:e41-e45.
16. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002;88:467-469.
17. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603.
18. Blankenberg S, Tiret T, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, for the AtheroGene Investigators. Interleukin 18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106:24-30.
19. Anderson JL, Carlquist JF, Home BD, Muhlestein JB. Cardiovascular pharmacogenomics: current status, future prospects. J Cardiovasc Phannacol Therapeut. 2003;8:71-83.
20. Martins TB, Roberts WL, Home B, Anderson JL, Muhlestein B, Carlquist J, Hill HR. Risk factor analysis of serum cytokines in coronary artery disease patients and controls using a multiplexed fluorescent immunoassay. J Invest Med. 2004;52:S127.